Hormonal contraception, hormone replacement therapy and specialty hormones have been the subject of controversial discussions in women’s health for decades. The predominant belief is that the benefits of hormonal treatments outweigh the risks, but research is needed to counterbalance reports that tend to exaggerate the risk and understate the benefits.
Global Leader in Safety Studies and Real-World Research
Kantar Health and ZEG Berlin, a Kantar Health company, provide the leading and most experienced team for safety studies on women’s healthcare and hormone treatments. We have extensive expertise in all types of non-interventional safety studies and have been deeply involved in the development of methodologies in this research field.
Specialized Research in Pharmacoepidemiology and Drug Surveillance
- Large-scale pharmacoepidemiological safety studies
- Non-interventional field studies
- Patient-based active surveillance (EURAS and INAS)
Data and Analytics on Patient Reported Outcomes for Women's Health
Whether you’re launching a new drug or determining a commercial strategy, Kantar Health has expertise and data to support your product and inform your decisions throughout the product lifecycle. Our proprietary information sources National Health and Wellness Survey and Epi Database® provide you with a holistic view of the patient and caregiver experience on women’s health issues.
See our latest published research on hormone therapy.
Learn more about our research solutions.